Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study
Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study is drawing significant interest across the industry.
Johnson & Johnson shared early AFib study results showing 90% success and no safety issues, but the stock lagged as healthcare stocks outperformed broader markets.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Clint Eastwood Produced An Oil Drama That's Perfect For Landman Fans
- Google Pixel 10A preorders come with a $100 gift card
- Don't fight the range, trade it: Shubham Agarwal
- Weekend Planner (Feb 14-Feb 15): Delhi-NCR residents, you must check this out!
Source: Original →